Benzinga | May 13, 2021 08:03AM EDT

Beyond Air Highlights Presentation Of Data In Hospitalized Patients With Viral Lung Infections From LungFit PRO Programs At ATS 2021

Interim analysis from the ongoing, open-label, randomized acute viral pneumonia (including COVID-19) pilot study shows 150 ppm nitric oxide (NO) administered with LungFit(r) PRO is well-tolerated with no treatment-related adverse events, and demonstrates encouraging efficacy signals



Further analysis of 3 previously reported pilot studies in bronchiolitis at 150-160 ppm NO demonstrates a favorable safety profile and consistent efficacy across multiple endpoints

Entirety of data at 150-160 ppm NO in both adult and infant patient populations supports further development of LungFit(r) PRO in patients hospitalized with viral pneumonia

GARDEN CITY, N.Y., May 13, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced the presentation of data at the American Thoracic Society (ATS) International Conference 2021, which is being held virtually from May 14 -- May 19. The data from both LungFit(r) PRO programs, acute viral pneumonia (including COVID-19) and bronchiolitis, show a favorable safety profile and encouraging efficacy trends using high concentration inhaled NO for the treatment of acute viral lung infections in hospitalized patients.

"We have now demonstrated a consistently favorable safety profile at high concentrations of nitric oxide in both adult and infant populations with acute viral lung infections," said Steve Lisi, Chairman and Chief Executive Officer of Beyond Air. "The new data from the acute viral pneumonia pilot trial in adults, taken together with our three previously completed pilot clinical trials in bronchiolitis, enable Beyond Air to prepare for a pivotal study for high concentration NO in a viral indication."

"The interim analysis of patients in the acute viral pneumonia (including COVID-19) pilot study shows a favorable safety profile and encouraging efficacy signals in this adult patient population treated with 150 ppm NO generated and delivered by LungFit(r) PRO," commented Andrew Colin, M.D., Batchelor Family Professor of Cystic Fibrosis and Pediatric Pulmonology Director, Division of Pediatric Pulmonology, Miller School of Medicine, University of Miami. "Given these current data, I believe the results support the continued development of high concentration inhaled NO that can be delivered with ease by LungFit(r) for the treatment of viral pneumonia including COVID-19. LungFit(r) PRO is a revolutionary device that can allow for the treatment of this diverse patient population on a large scale".